-+ 0.00%
-+ 0.00%
-+ 0.00%

Cuprina And Ferti-Craft Collaborate To Obtain HSA Approval For 14 IVF Media SKUs Ahead Of 2026 Launch

Benzinga·05/05/2025 14:45:35
Listen to the news

uprina will collaborate with Ferti-Craft to prepare and submit the required regulatory dossiers for registration with Singapore Health Sciences Authority ("HSA"). The goal is to obtain approval for 14 IVF media product SKUs. The project aims to secure HSA approval for commercial sale before the fourth quarter of 2026.

Ferti-Craft will be responsible for obtaining all necessary documentation and testing certificates required by HSA, arranging the selection and logistics of all raw materials required for the production of these SKUs, and contributing the intellectual property, subject matter expertise on human assisted reproductive technology ("ART"), and production know-how on the preparation of these SKUs.

Subject to obtaining the necessary regulatory approvals, the facility is expected to commence producing commercialized product by the fourth quarter of 2026. Ferti-Craft expects initial sales to be primarily in Singapore, with an expanded presence to follow in select ASEAN countries, the Middle East and other global markets.